Company Description:
Specialty Contractors
Specialty Contractors
Construction Executive Online
Construction Job Openings
Company News
- Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - The Manila Times (news.google.com)
- Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 - TradingView (news.google.com)
- Snow Lake Phase 2 Drill Program Underway at Engo Valley - Newsfile (news.google.com)
- BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire (news.google.com)
- Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - The Manila Times (news.google.com)
- Bridge Biotherapeutics has failed to demonstrate its effectiveness in phase 2 clinical trials of its.. - 매일경제 (news.google.com)
- GGIP: A Multi-Energy Project to Support Iraq Towards Its Energy Independence - TotalEnergies.com (news.google.com)
- Breakthrough: New Gene Editing Drug Cuts Bad Cholesterol by 53% in Heart Disease Patients - Stock Titan (news.google.com)
- Vantage Biosciences Doses First Patient in Phase 2 Clinical - GlobeNewswire (news.google.com)
- Northern Lights: the First Major Carbon Capture and Storage Project in Norway - TotalEnergies.com (news.google.com)
- Revolutionary Obesity Treatment Takes On GLP-1 Side Effects: FDA Green-Lights Phase 2 Trial - Stock Titan (news.google.com)
- Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class - Endpoints News (news.google.com)
- Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - PR Newswire (news.google.com)
- Shell and Partners to Drive $700M Phase 2 of Northern Lights Project - Yahoo Finance (news.google.com)
- Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial - Stock Titan (news.google.com)
- Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewswire (news.google.com)
- Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels | Eli Lilly and Company - Eli Lilly and Company (news.google.com)
- Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy - BioSpace (news.google.com)
- Wave to submit Duchenne drug for approval after Phase 2 success - statnews.com (news.google.com)
- Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire (news.google.com)
- NMG's Massive Battery Materials Project Locks In Panasonic and GM as Key Customers - Stock Titan (news.google.com)
- NMG Issues Updated Feasibility Study for its Integrated Phase-2 Ore-to-Active-Anode-Material Operations: the Matawinie Mine and the Bécancour Battery Material Plant - Yahoo Finance (news.google.com)
- Merck & Co. pens $200M upfront deal for Hengrui's midstage heart disease med - Fierce Biotech (news.google.com)
- Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - GlobeNewswire (news.google.com)
- Genome & Company halts phase 2 microbiome immunotherapy trial in bile duct cancer - koreabiomed.com (news.google.com)
- Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza - Purdue University (news.google.com)
- Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II - BioSpace (news.google.com)
- Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire (news.google.com)
- PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Yahoo Finance (news.google.com)
- MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - GlobeNewswire (news.google.com)
- Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire (news.google.com)
- Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - GlobeNewswire (news.google.com)
- Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire (news.google.com)
- In Early-Phase Pancreatic Cancer Clinical Trial, Investigational mRNA Vaccine Induces Sustained Immune Activity in Small Patient Group - Memorial Sloan Kettering Cancer Center (news.google.com)
- Medicus Pharma Provides Update on SKNJCT-003 Phase 2 - GlobeNewswire (news.google.com)
- Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Yahoo Finance (news.google.com)
- MiNK Therapeutics to Present Updated Data from Phase 2 - GlobeNewswire (news.google.com)
- Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress - PR Newswire (news.google.com)
- Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire (news.google.com)
- Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Yahoo Finance (news.google.com)
- Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - GlobeNewswire (news.google.com)
- Recursion Presents Phase 2 Data for REC-994 in CCM in - GlobeNewswire (news.google.com)
- EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - EyePoint Pharmaceuticals (news.google.com)
- Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study - GlobeNewswire (news.google.com)
- Air Taxi Company Completes Phase 2 of Piloted Flight Tests - IoT World Today (news.google.com)
- Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire (news.google.com)
- RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer - PR Newswire (news.google.com)
- D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH - Business Wire (news.google.com)
- CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire (news.google.com)
- CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options - Yahoo Finance (news.google.com)
- PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire (news.google.com)
- The Wharf Phase 2 - Greenroofs.com (news.google.com)
- Ryan Companies breaks ground on Phase 2 of 17 North Corporate Center - AZ Big Media (news.google.com)
- RION Announces Final Patient Enrolled in the Phase 2 Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers - Business Wire (news.google.com)
- EyePoint Provides Company Update and Anticipated Development Milestones for 2025 - EyePoint Pharmaceuticals (news.google.com)
- AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia - Fierce Biotech (news.google.com)
- Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire (news.google.com)
- Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire (news.google.com)
- Viking Therapeutics Launches Phase 2 Trial for Oral Weight Loss Drug After Impressive Early Results - Stock Titan (news.google.com)
- MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications - BioSpace (news.google.com)
- MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications - Business Wire (news.google.com)
- CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - GlobeNewswire (news.google.com)
- Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Business Wire (news.google.com)
- Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy - Business Wire (news.google.com)
- Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire (news.google.com)
- Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewswire (news.google.com)
- OKC software company Phase 2 named best small employer on Top Workplace 2024 list - The Oklahoman (news.google.com)
- Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss - Business Wire (news.google.com)
- Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data - GlobeNewswire (news.google.com)
- Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - GlobeNewswire (news.google.com)
- Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator - Business Wire (news.google.com)
- Transposon to Present Results from Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS/FTD at the 35th International Symposium on ALS/MND - PR Newswire (news.google.com)
- Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewswire (news.google.com)
- Mirum plans 2025 Phase 2 trial testing fragile X treatment - Fragile X News Today (news.google.com)
- UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2 - Fierce Biotech (news.google.com)
- IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewswire (news.google.com)
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease - Business Wire (news.google.com)
- Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease - Business Wire (news.google.com)
- Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire (news.google.com)
- Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose | Eli Lilly and Company - Eli Lilly and Company (news.google.com)
- Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire (news.google.com)
- Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire (news.google.com)
- Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting - Business Wire (news.google.com)
- Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Business Wire (news.google.com)
- CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial - CytoDyn Inc. (news.google.com)
- Ventus gears up for phase 2 study of potential daily oral lupus drug after passing early-stage test - Fierce Biotech (news.google.com)
- EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - EyePoint Pharmaceuticals (news.google.com)
- Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire (news.google.com)
- Cerevance Announces Publication of Positive Phase 2 Results - GlobeNewswire (news.google.com)
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire (news.google.com)
- Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewswire (news.google.com)
- MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire (news.google.com)
- Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - Business Wire (news.google.com)
- IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire (news.google.com)
- IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy - Fierce Biotech (news.google.com)
- Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI) - Business Wire (news.google.com)
- New Renderings Showcase Related Companies and Wynn Resorts' Master Plan for Phase Two of Hudson Yards - New York YIMBY (news.google.com)
- First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity - PR Newswire (news.google.com)
- Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia - PR Newswire (news.google.com)
- IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study - PR Newswire (news.google.com)